MedTrace Logo

Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism

NCT04675255 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-08-03

No results posted yet for this study

Summary

A substudy of TMC114FD2HTX4004 that will perform glucose tolerance testing, adipose testing and MRI scan at baseline, 12 and 24 weeks post switch of ART medications.

Conditions

  • HIV I Infection
  • Adiposity

Interventions

PROCEDURE

Frequently sampled glucose tolerance testing

Frequently sampled glucose tolerance testing

PROCEDURE

abdominal subcutaneous adipose tissue biopsy

abdominal subcutaneous adipose tissue biopsy

PROCEDURE

MRI scan to assess intrahepatic triglyceride content

MRI scan to assess intrahepatic triglyceride content

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Jane O'Halloran, MB BA PhD · Washington University School of Medicine in St. Louis

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-06-08
Completion
2023-06-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675255 on ClinicalTrials.gov